Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1.

Mol Ther Oncolytics · 2019 · PMC6880119 · PMID 31788554

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

No significant changes were observed in the levels of T cell immunoglobulin and ITIM domain (TIGIT) expression among all groups, although there was a decreasing trend observed in the group treated with oHSV2-aPD1 ( Figure 5 G).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.